{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "12516545", "DateCompleted": {"Year": "2003", "Month": "01", "Day": "30"}, "DateRevised": {"Year": "2014", "Month": "11", "Day": "20"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0014-2980", "JournalIssue": {"Volume": "32", "Issue": "12", "PubDate": {"Year": "2002", "Month": "Dec"}}, "Title": "European journal of immunology", "ISOAbbreviation": "Eur J Immunol"}, "ArticleTitle": "The anti-inflammatory sesquiterpene lactone parthenolide suppresses IL-4 gene expression in peripheral blood T.", "Pagination": {"StartPage": "3587", "EndPage": "3597", "MedlinePgn": "3587-97"}, "Abstract": {"AbstractText": ["Sesquiterpene lactones (SL) derived from Mexican India medicinal plants and parthenolide, the major SL from European feverfew, have raised considerable interest because of their anti-inflammatory and complex pharmacological action. Interleukin-4 (IL-4) is a key cytokine that influences the development of T helper 2 cells and plays an important role in the pathogenesis of allergic diseases. We show here that the anti-inflammatory parthenolide suppresses IL-4 expression at the mRNA and the protein levels in a dose-dependent manner. We demonstrate that parthenolide blocks NF-kappaB binding to two important IL-4 promoter regulatory elements and suppresses promoter activity upon T cell activation. Differences regarding the effects of parthenolide on expression levels of IL-4, IL-2 and IFN-gamma were observed. Parthenolide (2.5 microM) could completely suppress IL-4 protein levels secreted in anti-CD3/CD28-stimulated peripheral blood T cells from allergic and normal donors. Complete inhibition of IL-2 and IFN-gamma requires higher doses of parthenolide. So far, drugs directed against IL-4 expression have not been described. This finding raises the potential to develop parthenolide to treat IL-4-mediated allergic-like inflammation."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Tumorimmunology Program, German Cancer Research Center, Heidelberg, Germany. m.li-weber@dkfz-heidelberg.de"}], "Identifier": [], "LastName": "Li-Weber", "ForeName": "Min", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Giaisi", "ForeName": "Marco", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Treiber", "ForeName": "Monika K", "Initials": "MK"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Krammer", "ForeName": "Peter H", "Initials": "PH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Eur J Immunol", "NlmUniqueID": "1273201", "ISSNLinking": "0014-2980"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents, Non-Steroidal"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-2"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Messenger"}, {"RegistryNumber": "0", "NameOfSubstance": "Sesquiterpenes"}, {"RegistryNumber": "207137-56-2", "NameOfSubstance": "Interleukin-4"}, {"RegistryNumber": "2RDB26I5ZB", "NameOfSubstance": "parthenolide"}, {"RegistryNumber": "82115-62-6", "NameOfSubstance": "Interferon-gamma"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Anti-Inflammatory Agents, Non-Steroidal"}, {"QualifierName": ["genetics"], "DescriptorName": "Binding Sites"}, {"QualifierName": ["drug effects"], "DescriptorName": "Down-Regulation"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": ["genetics"], "DescriptorName": "Interferon-gamma"}, {"QualifierName": ["genetics"], "DescriptorName": "Interleukin-2"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Interleukin-4"}, {"QualifierName": [], "DescriptorName": "Jurkat Cells"}, {"QualifierName": [], "DescriptorName": "Lymphocyte Activation"}, {"QualifierName": ["metabolism"], "DescriptorName": "NF-kappa B"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Promoter Regions, Genetic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Protein Binding"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "RNA, Messenger"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Sesquiterpenes"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "T-Lymphocytes"}, {"QualifierName": ["drug effects"], "DescriptorName": "Transcription, Genetic"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2003", "Month": "1", "Day": "9", "Hour": "4", "Minute": "0"}, {"Year": "2003", "Month": "1", "Day": "31", "Hour": "4", "Minute": "0"}, {"Year": "2003", "Month": "1", "Day": "9", "Hour": "4", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["12516545", "10.1002/1521-4141(200212)32:12<3587::AID-IMMU3587>3.0.CO;2-E"]}}], "PubmedBookArticle": []}